HMGN5

Summary

HMGN5 (high mobility group nucleosome binding domain 5, HGNC:8013) is a protein-coding gene on chromosome Xq21.1, encoding High mobility group nucleosome-binding domain-containing protein 5 (P82970). Preferentially binds to euchromatin and modulates cellular transcription by counteracting linker histone-mediated chromatin compaction.

This gene encodes a nuclear protein with similarities to the high mobility group proteins, HMG14 and HMG17, which suggests that this protein may function as a nucleosomal binding and transcriptional activating protein.

Source: NCBI Gene 79366 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 64 total — 1 pathogenic
• MANE Select transcript: NM_030763

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8013
Approved symbol	HMGN5
Name	high mobility group nucleosome binding domain 5
Location	Xq21.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000198157
Ensembl biotype	protein_coding
OMIM	300385
Entrez	79366

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 25 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000358130, ENST00000373250, ENST00000430960, ENST00000436386, ENST00000447319, ENST00000451455, ENST00000491275, ENST00000883543, ENST00000883544, ENST00000883545, ENST00000883546, ENST00000883547, ENST00000883548, ENST00000916825, ENST00000916826, ENST00000916827, ENST00000916828, ENST00000916829, ENST00000916830, ENST00000916831, ENST00000966202, ENST00000966203, ENST00000966204, ENST00000966205, ENST00000966206, ENST00000966207

RefSeq mRNA: 1 — MANE Select: NM_030763 NM_030763

CCDS: CCDS14448

Canonical transcript exons

ENST00000358130 — 7 exons

Exon	Start	End
ENSE00001401828	81113699	81115230
ENSE00001407782	81121535	81121672
ENSE00001679518	81201737	81201913
ENSE00001770506	81118730	81118759
ENSE00003506379	81118432	81118485
ENSE00003517004	81119788	81119817
ENSE00003786792	81116204	81116341

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 97.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.0168 / max 868.3864, expressed in 1298 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199849	4.9800	848
199850	2.9240	731
199852	1.3059	512
199848	0.4040	182
199851	0.4028	208

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	97.88	gold quality
right testis	UBERON:0004534	97.17	gold quality
left testis	UBERON:0004533	96.77	gold quality
testis	UBERON:0000473	95.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.55	gold quality
adenohypophysis	UBERON:0002196	89.98	gold quality
ganglionic eminence	UBERON:0004023	89.60	gold quality
spinal cord	UBERON:0002240	89.09	gold quality
right adrenal gland	UBERON:0001233	88.99	gold quality
right adrenal gland cortex	UBERON:0035827	88.60	gold quality
colonic epithelium	UBERON:0000397	88.57	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.45	gold quality
left adrenal gland	UBERON:0001234	88.28	gold quality
ventricular zone	UBERON:0003053	88.17	gold quality
left adrenal gland cortex	UBERON:0035825	87.96	gold quality
amygdala	UBERON:0001876	87.37	gold quality
pituitary gland	UBERON:0000007	87.18	gold quality
anterior cingulate cortex	UBERON:0009835	87.06	gold quality
metanephros cortex	UBERON:0010533	86.99	gold quality
cingulate cortex	UBERON:0003027	86.91	gold quality
islet of Langerhans	UBERON:0000006	86.68	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.47	gold quality
adrenal cortex	UBERON:0001235	86.39	gold quality
adrenal gland	UBERON:0002369	86.35	gold quality
corpus epididymis	UBERON:0004359	86.12	gold quality
left ovary	UBERON:0002119	85.64	gold quality
rectum	UBERON:0001052	85.53	gold quality
left uterine tube	UBERON:0001303	85.39	gold quality
hypothalamus	UBERON:0001898	85.31	gold quality
caudate nucleus	UBERON:0001873	85.29	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	140.50
E-HCAD-6	yes	42.36
E-GEOD-134144	yes	33.52
E-ANND-3	yes	8.98
E-MTAB-6524	no	234.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

55 targeting HMGN5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-3913-5P	99.78	67.26	968
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-7154-5P	99.69	70.52	1900

Literature-anchored findings (GeneRIF, showing 30)

• The structure of the HMGN5 gene and the known properties of the HMGN5 protein, are described. (PMID:20123071)
• A positive correlation was observed between NSBP1 expression and cell proliferation and apoptosis in DU145 cells. (PMID:20531280)
• The data of study suggested that HMGN5 may play a critical role in the development of gliomas. (PMID:21373965)
• HMGN5 has a highly disordered structure, binds dynamically to nucleosome core particles, modulates the binding of H1 to chromatin, reduces the compaction of the chromatin fiber, and affects transcription. (PMID:21518955)
• these results suggest that NSBP1 promotes the viability of bladder cancer cells through increased cell proliferation (PMID:21695596)
• NSBP1 plays oncogenic role in clear cell renal cell carcinoma (ccRCC) by promoting cell proliferation and invasion. (PMID:22420896)
• HMGN5 may be a potential molecular target with therapeutic relevance for the treatment of prostate cancer. (PMID:22504871)
• HMGN5 silencing to significantly inhibit A549 and H1299 cell proliferation. (PMID:22994738)
• Data indicate that cells lacking either high mobility group protein N5 (HMGN5) and lamina-associated polypeptide 2alpha (LAP2alpha) showed that loss of either protein affects the genome-wide distribution of the remaining partner. (PMID:23673662)
• HMGN5 is a critical factor in the development of chemoresistance through regulating autophagy, and it offers a novel target for improving osteosarcoma therapy. (PMID:24664583)
• HMGN5 plays oncogenic role in osteosarcoma by promoting cell proliferation and invasion, and could be exploited as a target for therapy in osteosarcoma. (PMID:24687550)
• HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation (PMID:25307178)
• HMGN5 plays an oncogenic role in human breast cancer by inhibiting cell proliferation and invasion, and activating apoptosis, which could be exploited as a target for therapy in human breast cancer. (PMID:25315189)
• HMGN5 is an oncogene and plays an important role in prostate cancer tumorigenesis and progression. the level of HMGN5 may be used as a biomarker to predict the patients that would benefit from gemcitabine treatment. (PMID:25572120)
• High HMGN5 expression is associated with urothelial bladder cancer. (PMID:25796505)
• Our data first time identified miR-186 as the upstream regulator of NSBP1 (PMID:26290438)
• HMGN5 overexpression is correlated with advanced pathological grade and poorer prognosis in meningiomas (PMID:26315299)
• Decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5. (PMID:26394192)
• NSBP1 was highly expressed in NSCLC cells. NSBP1 siRNA knockdown suppressed NSCLC cell proliferation and invasion. miR326 has a putative binding site in the NSBP1 3’UTR. NSBP1 overexpression abolished miR326 inhibition of cyclin B1 and MMP9 expression. (PMID:26548724)
• We observed decreased miR-409-3p expression in glioma, and overexpression of miR-409-3p repressed glioma cell invasion and proliferation by targeting HMGN5, an oncogene associated with glioma (PMID:28109076)
• Findings suggest that a miR-140-5p/HMGN5/autophagy regulatory loop plays a critical role in chemoresistance in osteosarcoma. In conclusion, our data elucidated that miR-140-5p promoted autophagy mediated by HMGN5 and sensitized osteosarcoma cells to chemotherapy. (PMID:28341864)
• High HMGN5 expression is associated with osteosarcoma invasion. (PMID:28627703)
• HMGN5 regulated the expression of multidrug resistance 1, cyclin B1, and Bcl-2. (PMID:28914995)
• HMGN5 mRNA levels were significantly elevated in bladder transitional cell carcinoma tissue compared to controls. (PMID:29509244)
• MiR-183-3p regulated HMGN5 expression in prostate cancer cells. (PMID:31314587)
• HIF1A upregulated the transcription factor GATA1 and further promoted the expression of HMGN5. (PMID:31930127)
• HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells. (PMID:32596388)
• Prognostic value of HMGN family expression in acute myeloid leukemia. (PMID:33467898)
• HMGN5 promotes invasion and migration of colorectal cancer through activating FGF/FGFR pathway. (PMID:33629303)
• Spatial and Temporal Expression of High-Mobility-Group Nucleosome-Binding (HMGN) Genes in Brain Areas Associated with Cognition in Individuals with Down Syndrome. (PMID:34946949)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Hmgn5	ENSMUSG00000031245
rattus_norvegicus	Hmgn5	ENSRNOG00000029078
rattus_norvegicus		ENSRNOG00000064141
rattus_norvegicus	Hmgn5b	ENSRNOG00000065214

Protein

Protein identifiers

High mobility group nucleosome-binding domain-containing protein 5 — P82970 (reviewed: P82970)

Alternative names: Nucleosome-binding protein 1

All UniProt accessions (6): P82970, Q5JSK6, Q5JSK7, Q5JSK8, Q5JSK9, Q5JSL0

UniProt curated annotations — full annotation on UniProt →

Function. Preferentially binds to euchromatin and modulates cellular transcription by counteracting linker histone-mediated chromatin compaction.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitously expressed.

Domain organisation. Specifically targeted by its C-terminus to nucleosomes in euchromatin.

Similarity. Belongs to the HMGN family.

RefSeq proteins (1): NP_110390* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000079	HMGN_fam	Family
IPR040164	HMGN5	Family

Pfam: PF01101

UniProt features (16 total): compositionally biased region 7, cross-link 4, modified residue 3, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P82970-F1	52.89	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 76, 93, 67, 101, 101, 124, 31

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 166 (showing top): MULLIGHAN_NPM1_SIGNATURE_3_UP, MODULE_255, MODULE_317, RODRIGUES_NTN1_TARGETS_UP, KOYAMA_SEMA3B_TARGETS_UP, AACTTT_UNKNOWN, LEF1_Q6, MILI_PSEUDOPODIA_CHEMOTAXIS_UP, VECCHI_GASTRIC_CANCER_EARLY_DN, HAN_SATB1_TARGETS_DN, GATA4_Q3, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, BERENJENO_TRANSFORMED_BY_RHOA_UP, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP, AR_01

GO Biological Process (6): chromatin organization (GO:0006325), regulation of DNA-templated transcription (GO:0006355), positive regulation of cell population proliferation (GO:0008284), positive regulation of gene expression (GO:0010628), negative regulation of apoptotic process (GO:0043066), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (4): chromatin binding (GO:0003682), RNA binding (GO:0003723), nucleosomal DNA binding (GO:0031492), DNA binding (GO:0003677)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
regulation of gene expression	2
nucleic acid binding	2
cellular anatomical structure	2
intracellular membrane-bounded organelle	2
cellular component organization	1
regulation of RNA biosynthetic process	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
binding	1
chromatin DNA binding	1
nucleosome binding	1
chromosome	1
nuclear lumen	1
cytoplasm	1

Protein interactions and networks

STRING

778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HMGN5	HMGN1	P05114	956
HMGN5	HMGN2	P05204	905
HMGN5	ZNF219	Q9P2Y4	750
HMGN5	H1-0	P07305	581
HMGN5	HMGN3	Q15651	579
HMGN5	TSGA10	Q9BZW7	522
HMGN5	F2Z2I4	F2Z2I4	494
HMGN5	SPATA19	Q7Z5L4	464
HMGN5	HMGN4	O00479	453
HMGN5	TCEA2	Q15560	446
HMGN5	PSME3IP1	Q9GZU8	436
HMGN5	GLS2	Q9UI32	417
HMGN5	TSPY1	P09002	411
HMGN5	H1-3	P16402	402
HMGN5	HDAC4	P56524	397

IntAct

24 interactions, top by confidence:

A	B	Type	Score
HGS	STAM2	psi-mi:“MI:0914”(association)	0.550
SNRNP27	UBA6	psi-mi:“MI:0914”(association)	0.530
USP47	DENR	psi-mi:“MI:0914”(association)	0.530
CYP1A1	SNX3	psi-mi:“MI:0914”(association)	0.530
DLGAP4	HMGN5	psi-mi:“MI:0915”(physical association)	0.400
HMGN5	HNRNPCL2	psi-mi:“MI:0915”(physical association)	0.400
HMGN5	NOTCH1	psi-mi:“MI:0915”(physical association)	0.370
GTF2E2	UBA6	psi-mi:“MI:0914”(association)	0.350
ARHGEF19	NUP42	psi-mi:“MI:0914”(association)	0.350
FGD1	MECP2	psi-mi:“MI:0914”(association)	0.350
PTPN2	GOLIM4	psi-mi:“MI:0914”(association)	0.350
CBX8	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
HMGN5	SMCHD1	psi-mi:“MI:0914”(association)	0.350
GTF2E2	STX7	psi-mi:“MI:0914”(association)	0.350
RPL35A	SMCHD1	psi-mi:“MI:0914”(association)	0.350
HSPA2	HGS	psi-mi:“MI:0914”(association)	0.350
USP47	LAMTOR5	psi-mi:“MI:0914”(association)	0.350
KLHL20	RAD21	psi-mi:“MI:0914”(association)	0.350
B3GALT2	LIG1	psi-mi:“MI:0914”(association)	0.350
CREB1	ACOT7	psi-mi:“MI:0914”(association)	0.350
PPIL4	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
RPS11	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (166): HMGN5 (Co-fractionation), HMGN5 (Co-fractionation), HMGN5 (Co-fractionation), HMGN5 (Co-fractionation), HMGN5 (Co-fractionation), HMGN5 (Affinity Capture-MS), HMGN5 (Affinity Capture-MS), HMGN5 (Affinity Capture-MS), HMGN5 (Affinity Capture-MS), HMGN5 (Two-hybrid), HMGN5 (Affinity Capture-MS), HMGN5 (Affinity Capture-MS), HMGN5 (Proximity Label-MS), DLGAP4 (Proximity Label-MS), HMGN5 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D9BZF0, A0A571BEE2, A6H8Y1, A8MU46, B3EWZ0, B4F777, D3YVF0, F4K4Y5, O01949, O43493, O43719, O46383, O81283, P08116, P13816, P24587, P27058, P27123, P43597, P48785, P53911, P82970, Q01033, Q10P83, Q14093, Q17Q32, Q28092, Q5H9L2, Q5MJ10, Q5RB63, Q5XHX6, Q6AXX0, Q6P902, Q6SJ82, Q84JB7, Q8BGC0, Q8IZU1, Q8VYD2, Q9D498, Q9FGW9

Diamond homologs: B4F777, P82970, Q9JL35, O00479, P02314, P02316, P05114, P05204, P12274, P12902, P18608, Q15651, Q3ZBV4, Q5R715, Q66H40, Q9DCB1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	12
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
154612	GRCh38/hg38 Xq21.1(chrX:80921556-83715625)x0	Pathogenic

SpliceAI

916 predictions. Top by Δscore:

Variant	Effect	Δscore
X:81115226:GGTGC:G	acceptor_gain	1.0000
X:81115227:GTGC:G	acceptor_gain	1.0000
X:81115228:TGC:T	acceptor_gain	1.0000
X:81115229:GC:G	acceptor_gain	1.0000
X:81115229:GCCT:G	acceptor_loss	1.0000
X:81115230:CC:C	acceptor_gain	1.0000
X:81115231:C:A	acceptor_loss	1.0000
X:81115231:C:CC	acceptor_gain	1.0000
X:81115233:G:GC	acceptor_gain	1.0000
X:81115237:G:C	acceptor_gain	1.0000
X:81115237:G:GC	acceptor_gain	1.0000
X:81115239:A:AC	acceptor_gain	1.0000
X:81115239:A:C	acceptor_gain	1.0000
X:81115242:G:C	acceptor_gain	1.0000
X:81115242:G:GC	acceptor_gain	1.0000
X:81116200:ATACC:A	donor_loss	1.0000
X:81116202:A:AC	donor_gain	1.0000
X:81116203:C:CC	donor_gain	1.0000
X:81116203:CCT:C	donor_gain	1.0000
X:81116205:T:TA	donor_gain	1.0000
X:81116337:ATTTT:A	acceptor_gain	1.0000
X:81116338:TTTT:T	acceptor_gain	1.0000
X:81116339:TTT:T	acceptor_gain	1.0000
X:81116340:TT:T	acceptor_gain	1.0000
X:81116342:C:CC	acceptor_gain	1.0000
X:81116342:CTG:C	acceptor_loss	1.0000
X:81116343:T:C	acceptor_loss	1.0000
X:81116346:C:CT	acceptor_gain	1.0000
X:81116346:C:T	acceptor_gain	1.0000
X:81116347:A:T	acceptor_gain	1.0000

AlphaMissense

1904 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:81121538:T:A	R4S	0.985
X:81121538:T:G	R4S	0.985
X:81118751:T:A	R18S	0.984
X:81118751:T:G	R18S	0.984
X:81118748:T:A	R19S	0.983
X:81118748:T:G	R19S	0.983
X:81118739:C:A	R22S	0.977
X:81118739:C:G	R22S	0.977
X:81118749:C:G	R19T	0.965
X:81118752:C:G	R18T	0.961
X:81118740:C:G	R22T	0.959
X:81121539:C:G	R4T	0.959
X:81118740:C:A	R22M	0.956
X:81118737:A:G	L23S	0.955
X:81121541:T:A	K3N	0.944
X:81121541:T:G	K3N	0.944
X:81118743:G:T	A21D	0.938
X:81121545:G:T	P2H	0.938
X:81121535:C:A	K5N	0.935
X:81121535:C:G	K5N	0.935
X:81118741:T:C	R22G	0.933
X:81118754:C:A	K17N	0.930
X:81118754:C:G	K17N	0.930
X:81118750:T:C	R19G	0.917
X:81121545:G:A	P2L	0.907
X:81121539:C:A	R4I	0.905
X:81118749:C:A	R19I	0.904
X:81118753:T:C	R18G	0.897
X:81118746:G:A	S20F	0.896
X:81118737:A:C	L23W	0.893

dbSNP variants (sampled 300 via entrez): RS1000071236 (X:81199650 G>A,T), RS1000077159 (X:81150004 A>G), RS1000124749 (X:81198847 T>C), RS1000178528 (X:81189775 G>A), RS1000208398 (X:81143792 G>T), RS1000215737 (X:81175225 G>A), RS1000244597 (X:81198737 G>A), RS1000284967 (X:81118348 A>C), RS1000313802 (X:81188672 T>C), RS1000341392 (X:81182319 T>A,C), RS1000374037 (X:81169336 A>G), RS1000374952 (X:81179199 C>T), RS1000381743 (X:81125946 G>C), RS1000402966 (X:81119523 G>C), RS1000426721 (X:81198475 T>C)

Disease associations

OMIM: gene MIM:300385 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_94	Refractive error	2.000000e-09

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, affects cotreatment, increases expression, affects expression	5
Air Pollutants	decreases expression, increases abundance, increases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
ochratoxin A	affects cotreatment, decreases expression, increases expression	2
Cadmium	decreases expression, increases abundance	2
Estradiol	affects expression, decreases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance	2
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
bisphenol A	affects cotreatment, increases methylation	1
trichostatin A	increases expression	1
beta-lapachone	decreases expression	1
butyraldehyde	increases expression	1
zinc chromate	increases expression, increases abundance	1
pentanal	increases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
Temozolomide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	decreases reaction, increases activity, decreases response to substance	1
Citrinin	affects cotreatment, decreases expression	1
Copper	affects binding, decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A4Y4	SEES3-1V human NSBP1, clone1	Embryonic stem cell	Male
CVCL_A4Y5	SEES3-1V human NSBP1, clone2	Embryonic stem cell	Male
CVCL_A4Y6	SEES3-1V human NSBP1, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.